Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.65 USD | +2.66% | +4.17% | -33.47% |
05-09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
05-09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.47% | 911M | |
+33.34% | 49.46B | |
+1.79% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.76% | 26.61B | |
-21.85% | 18.64B | |
+7.87% | 13.16B | |
+29.51% | 12.55B | |
+23.72% | 12.1B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q3 Revenue $72,000